Berliner D, Bauersachs J
Dept. of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Herz. 2018 May;43(3):207-213. doi: 10.1007/s00059-017-4668-9.
The prevalence of heart failure increases with age. Changes in the age distribution and growing life expectancy will lead to a further rise. However, data concerning drug treatment of heart failure especially in the elderly are scarce. Subgroup analyses of the heart failure trials suggest that drug therapy in older patients should follow the recommendations in the current guidelines. In doing so, several common comorbidities in these patients (e. g., impaired renal function) have to be considered and may have an influence on the therapy (e. g., drug dose, choice of active pharmaceutical ingredient, etc.). Especially in old, multimorbid patients, possible interaction of drugs might play a substantial role. In many cases the main goal of the therapy, especially in the very elderly, is to improve symptoms and quality of life.
心力衰竭的患病率随年龄增长而增加。年龄分布的变化和预期寿命的延长将导致患病率进一步上升。然而,关于心力衰竭药物治疗的数据,尤其是老年患者的数据稀缺。心力衰竭试验的亚组分析表明,老年患者的药物治疗应遵循现行指南中的建议。在此过程中,必须考虑这些患者的几种常见合并症(如肾功能受损),并且这些合并症可能会对治疗产生影响(如药物剂量、活性药物成分的选择等)。特别是在老年、患有多种疾病的患者中,药物之间可能的相互作用可能起重要作用。在许多情况下,治疗的主要目标,尤其是在高龄患者中,是改善症状和生活质量。